Agrochemicals company Insecticides (India) announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations: Rs 358.92 crore in Q4FY25, showing a 32% growth compared to Rs 272.50 crore in Q4FY24. Gross Profit: Rs 131.36 crore in Q4FY25, showing a 51% growth compared to Rs 86.84 crore in Q4FY24. EBITDA: Rs 28.47 crore in Q4FY25, showing a 226% growth compared to Rs 8.73 crore in Q4FY24. EBITDA Margin (%): 7.9% in Q4FY25, compared to 3.2% in Q4FY24. Profit After Tax: Rs 13.89 crore in Q4FY25, showing an 85% growth compared to Rs 7.52 crore in Q4FY24. FY25 Financial Highlights: Revenue from Operations: Rs 1,999.95 crore in FY25, showing a 2% growth compared to Rs 1,966.39 crore in FY24. Gross Profit: Rs 640.83 crore in FY25, showing a 28% growth compared to Rs 501.36 crore in FY24. EBITDA: Rs 221.22 crore in FY25, showing a 36% growth compared to Rs 162.32 crore in FY24. EBITDA Margin (%): 11.1% in FY25, compared to 8.3% in FY24. Profit After Tax: Rs 142.02 crore in FY25, showing a 39% growth compared to Rs 102.07 crore in FY24. Commenting on the results and performance, Rajesh Kumar Aggarwal, MD of Insecticides (India) said: “We are pleased to report a robust performance of the Company, marked by strong execution and strategic discipline, resulting in a profit growth of 39% in FY25. This performance underscores the success of the strategic framework we established —centered around profitable growth, a sharper focus on premium products, and margin enhancement. The overall business environment remained favorable throughout the year. A good monsoon and healthy reservoir levels provided strong tailwinds for rural demand and agri-input consumption. Additionally, stable raw material prices and our deep farmer connect further supported steady demand across markets. Our continued focus on premiumization yielded positive results, driving an improvement in gross margins. We consciously prioritized value over volume, reflecting our long-term strategy of sustainable, profitable growth. This disciplined approach also led to an improvement in key return metrics, with both ROCE and ROE improving consistently even in FY25, a direct outcome of better product mix and efficient capital allocation. Looking ahead, we remain optimistic about the upcoming seasons. We expect continued momentum supported by favorable macro tailwinds such as a strong monsoon forecast and stable raw material prices. Our growth outlook remains intact, with expectations of expansion in premium products, stable gross profit margins, and EBITDA improvement, driven by new launches and operational efficiencies. Recently we also launched Altair, a patented pre-emergent herbicide for paddy developed by Nissan Chemical Corporation, Japan, which will be exclusively marketed by us in India. This launch is a testament of our commitment to deliver innovative and effective solutions that address the real challenges faced by Indian farmers. With a robust product pipeline and planned launches in the coming year and in recent years, we are well-positioned to capture emerging opportunities in the market. While continued investment in future majorly at Dahej capacity expansion and upgraded technical and formulation facilities at Sotanala, Rajasthan. We remain deeply committed to sustainability, innovation, and responsible growth. As we move forward, our focus stays firmly on delivering long-term value for our stakeholders, while creating a positive impact on the environment and the communities we serve. With a strong foundation and clear vision, we are confident in building a resilient, promising future for our business.” Result PDF
Agrochemicals company Insecticides (India) announced Q3FY25 results Financial Highlights: Revenue from Operations for Q3FY25 remained stable at Rs 357.7 crore, similar to Rs 357.9 crore in Q3FY24. Gross Profit increased by 20% YoY to Rs 129.2 crore from Rs 108.0 crore, with Gross Profit Margin improving to 36.1% (vs. 30.2%). EBITDA grew by 19% YoY to Rs 30.9 crore from Rs 26.0 crore, with EBITDA Margin expanding to 8.6% from 7.3%. PAT saw a 42% YoY increase, reaching Rs 17.4 crore compared to Rs 12.3 crore in Q3FY24. Business Highlights: Robust growth in recent launches like Mission, Mission SC, Shinwa, Izuki in first nine months. B2B sales remain impacted with challenging macro market conditions. 10 new products launched in first nine months including patented latest technology products Launched Centran, a patented 9(3) insecticide with dual-action for paddy. It aims to boost productivity and support farmers' economic growth Torry Super an innovative 9(3) herbicide for maize which is based on SPF technology, developed by in-house R&D; team Tie up with BioPrime to brings Relieve, it is exclusive biological product for the Indian market, furthering efforts to provide sustainable solutions for Indian agriculture. Received Patent for IZUKI, a fungicide for paddy. This has been developed in technical collaboration with Nissan Chemical Corporation Japan Rajesh Aggarwal, MD of Insecticides (India) said: “We are excited to share our robust performance during current quarter with 42% growth in PAT. This is in line with the strategic framework established at start of the year focusing on profitable growth with higher share of Premium Products and improving its margins. The first nine months has been in line with expectations, driven by strong contributions from our premium product range, which now constitutes 62% of B2C revenue and significant improvements in our EBITDA margins. We are optimistic about the upcoming seasons, supported by favorable tailwinds such as a strong monsoon, increased reservoir levels, and enhanced crop sowing. Furthermore, government policies in latest Union Budget for increasing farmer income and thrust on increasing output for cotton, pulses etc. are expected to provide additional positive momentum. We are delighted to share that we have received an overwhelming response from market to our new launches providing latest technology and complete crop solution to the farmers. Our commitment to innovation remains steadfast as we continue to enhance our technology offerings for farmers. In Q2 FY25, we acquired Kaeros Research Private Limited aimed at securing supply chains and reducing costs through direct imports. Kaeros holds import licenses and vendor approvals, providing valuable benefits. The acquisition was executed at fair value and is accretive to shareholder value. The Company’s fully paid-up capital is Rs. 4.78 crores, with land assets situated in Shamli, Uttar Pradesh used for field trials. We remain committed to investing in cutting-edge technology, fostering innovation, and ensuring operational excellence to deliver sustainable, profitable growth. With a clear vision and a solid foundation, we are confident in our ability to generate lasting value for our stakeholders and build a promising future for our business.” Result PDF